| Paul Pfennig, ACNS-BC, FNP-BC, ANP | |
|
309 S Central Ave, Sidney, MT 59270-4127 | |
| (406) 488-5000 | |
| Not Available |
| Full Name | Paul Pfennig |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 14 Years |
| Location | 309 S Central Ave, Sidney, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043503113 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trihealth H Llc | 1850570458 | 668 |
News Archive
The Institute of Bioengineering and Nanotechnology (IBN) has developed a novel method to simultaneously control the size and morphology of nanoparticles, which can be used in pharmaceutical synthesis and novel biomedical applications.
Children's tendency to show ethnic/racial prejudice is greater when their friends exclude individuals on the basis of race and when their peer groups felt threatened by outsiders, finds a new study published in the May/June issue of the journal Child Development.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.
› Verified 1 days ago
| Entity Name | Trihealth G Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295862944 PECOS PAC ID: 0749222651 Enrollment ID: O20050601000358 |
News Archive
The Institute of Bioengineering and Nanotechnology (IBN) has developed a novel method to simultaneously control the size and morphology of nanoparticles, which can be used in pharmaceutical synthesis and novel biomedical applications.
Children's tendency to show ethnic/racial prejudice is greater when their friends exclude individuals on the basis of race and when their peer groups felt threatened by outsiders, finds a new study published in the May/June issue of the journal Child Development.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.
› Verified 1 days ago
| Entity Name | Trihealth H Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811215742 PECOS PAC ID: 1850570458 Enrollment ID: O20110128000356 |
News Archive
The Institute of Bioengineering and Nanotechnology (IBN) has developed a novel method to simultaneously control the size and morphology of nanoparticles, which can be used in pharmaceutical synthesis and novel biomedical applications.
Children's tendency to show ethnic/racial prejudice is greater when their friends exclude individuals on the basis of race and when their peer groups felt threatened by outsiders, finds a new study published in the May/June issue of the journal Child Development.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Pfennig, ACNS-BC, FNP-BC, ANP 309 S Central Ave, Sidney, MT 59270-4127 Ph: (406) 488-5000 | Paul Pfennig, ACNS-BC, FNP-BC, ANP 309 S Central Ave, Sidney, MT 59270-4127 Ph: (406) 488-5000 |
News Archive
The Institute of Bioengineering and Nanotechnology (IBN) has developed a novel method to simultaneously control the size and morphology of nanoparticles, which can be used in pharmaceutical synthesis and novel biomedical applications.
Children's tendency to show ethnic/racial prejudice is greater when their friends exclude individuals on the basis of race and when their peer groups felt threatened by outsiders, finds a new study published in the May/June issue of the journal Child Development.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.
› Verified 1 days ago
Sarah Farrow, APRN, AGNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 214 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-2100 Fax: 406-488-2551 | |
Janie R Darby, CNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 214 14th Ave Sw Ste 108, Sidney, MT 59270 Phone: 406-488-2277 Fax: 406-488-2530 | |
Ms. Patricia Irene Era, ARNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 214 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-2100 | |
Patti Iversen, APRNBC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 214 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-2525 Fax: 406-488-2527 | |
Wendy K Wiltzen, FNPC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 214 14th Ave Sw, Sidney, MT 59270 Phone: 406-488-2501 Fax: 406-488-2149 | |
Diane Savage, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 221 5th St Sw, Sidney, MT 59270 Phone: 406-433-4635 |